Free Trial

Nektar Therapeutics (NKTR) SEC Filings & 10K Form

Nektar Therapeutics logo
$1.01 +0.02 (+1.50%)
(As of 09:34 AM ET)

Recent Nektar Therapeutics SEC Filings

DateFilerForm TypeView
11/19/2024
2:17 PM
Nektar Therapeutics (Subject)
ROBIN HOWARD W (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2024
2:28 PM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2024
11:17 AM
EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Nektar Therapeutics (Subject)
Form SC 13G
11/14/2024
8:18 AM
Deep Track Capital, LP (Filed by)
Nektar Therapeutics (Subject)
Form SC 13G/A
11/08/2024
4:31 PM
BlackRock, Inc. (Filed by)
Nektar Therapeutics (Subject)
Form SC 13G
11/07/2024
3:31 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2024
7:52 AM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/20/2024
8:15 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2024
8:15 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2024
8:14 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2024
3:13 PM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/19/2024
2:45 PM
Nektar Therapeutics (Subject)
Zalevsky Jonathan (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/14/2024
5:02 PM
CHESS ROBERT (Reporting)
Nektar Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
11:15 PM
Nektar Therapeutics (Filer)
Form EFFECT
06/05/2024
4:30 PM
Nektar Therapeutics (Filer)
Form 424B3
05/28/2024
3:51 PM
Nektar Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
05/20/2024
8:12 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2024
8:13 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2024
8:14 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2024
3:36 PM
Deep Track Biotechnology Master Fund, Ltd. (Reporting)
Deep Track Capital, LP (Reporting)
KROIN DAVID (Reporting)
Nektar Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2024
3:20 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/26/2024
3:12 PM
Nektar Therapeutics (Filer)
Form ARS
04/17/2024
4:03 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/19/2024
3:38 PM
Nektar Therapeutics (Filer)
Form D
Notice of Exempt Offering of Securities 
03/15/2024
3:18 PM
Nektar Therapeutics (Subject)
TCG Crossover GP II, LLC (Filed by)
Form SC 13G
03/14/2024
3:30 PM
Deep Track Biotechnology Master Fund, Ltd. (Reporting)
Deep Track Capital, LP (Reporting)
KROIN DAVID (Reporting)
Nektar Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
03/05/2024
4:11 PM
Nektar Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/04/2024
3:20 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/04/2024
7:40 AM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/22/2024
7:16 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/22/2024
7:17 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/22/2024
7:19 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2024
2:50 PM
Nektar Therapeutics (Subject)
Zalevsky Jonathan (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/20/2024
2:51 PM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/16/2024
4:16 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2024
7:50 AM
Deep Track Capital, LP (Filed by)
Nektar Therapeutics (Subject)
Form SC 13G/A
01/10/2024
3:25 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/15/2023
5:05 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2023
5:05 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2023
5:07 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2023
11:18 AM
Nektar Therapeutics (Subject)
WHITFIELD ROY A (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!
11/27/2023
3:55 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/20/2023
7:58 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2023
8:00 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2023
8:02 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:NKTR) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners